Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 24;12(13):1250.
doi: 10.3390/healthcare12131250.

Preliminary Report of Nationwide COVID-19 Vaccine Compensation in Taiwan

Yi-An Lu  1 , Fu-Yuan Huang  1 , Hsin Chi  1   2 , Chien-Yu Lin  2   3 , Nan-Chang Chiu  1   2
Affiliations

Preliminary Report of Nationwide COVID-19 Vaccine Compensation in Taiwan

Yi-An Lu et al. Healthcare (Basel). .

Abstract

The potential adverse effects of coronavirus disease 2019 (COVID-19) vaccinations raise public concerns. Data from Taiwan's Vaccine Injury Compensation Program (VICP) can provide valuable insights. This study analyzed the preliminary application data for COVID-19 vaccine compensation in Taiwan's VICP, focusing on applicants receiving vaccines between March 2021 and June 2022. Among the 2941 adverse events, 113 cases (3.8%) were deemed causally associated with vaccination, 313 (10.6%) were indeterminate, and 2515 (85.5%) had no causal association. Nearly half (47.6%) of the applicants were over 60 years old, and 76.6% had a history of pre-existing chronic diseases. Among the 426 vaccine-associated or indeterminate cases, the most common causes were hematological diseases and thrombosis. There were 920 mortality cases reported, and 97.4% were unassociated with vaccination. Only five deaths were judged to be associated with the COVID-19 vaccination, all involving the adenovirus vector vaccine and thrombosis with thrombocytopenia syndrome. In conclusion, most compensation applications were not causally linked to vaccination. Compared to other countries, the number of applications in Taiwan's VICP is relatively high. These findings may indicate a need to adjust the application requirements for compensation in Taiwan's program.

Keywords: Vaccine Injury Compensation Program; coronavirus disease 2019 vaccine; vaccine adverse events.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Age distribution of applicants and their association with COVID-19 vaccines.
Figure 2
Figure 2
Diagnoses associated with compensation claims by vaccine type. Abbreviations: disease (dis.), Oxford/AstraZeneca (AZ), Moderna (MDN), Pfizer/BioNTech (BNT), and Medigen (MVC).
Figure 3
Figure 3
Diagnoses of Adverse Events Following Immunization in combined associated/indeterminate applicants by vaccine type. Abbreviations: disease (dis.), Oxford/AstraZeneca (AZ), Moderna (MDN), Pfizer/BioNTech (BNT), and Medigen (MVC).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Food and Drug Administration, Ministry of Health and Welfare TFDA Granted Emergency Use Authorization (EUA) for Four COVID-19 Vaccines in Taiwan. [(accessed on 30 March 2024)];2021 Available online: https://www.mohw.gov.tw/cp-115-64023-2.html.
    1. Su W.J., Arnold Chan K., Chuang J.H., Wang T.A., Chen S.F., Chang Y.C., Chen M.Y., Chang C.C., Yang C.H. Acute reactions after a homologous primary COVID-19 vaccination series: Analysis of Taiwan V-Watch data. Vaccine. 2023;41:2853–2859. doi: 10.1016/j.vaccine.2023.03.042. - DOI - PMC - PubMed
    1. Goddard K., Lewis N., Fireman B., Weintraub E., Shimabukuro T., Zerbo O., Boyce T.G., Oster M.E., Hanson K.E., Donahue J.G., et al. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022;40:5153–5159. doi: 10.1016/j.vaccine.2022.07.007. - DOI - PMC - PubMed
    1. Rosenblum H.G., Gee J., Liu R., Marquez P.L., Zhang B., Strid P., Abara W.E., McNeil M.M., Myers T.R., Hause A.M., et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: An observational study of reports to the Vaccine Adverse Event Reporting System and v-safe. Lancet Infect. Dis. 2022;22:802–812. doi: 10.1016/s1473-3099(22)00054-8. - DOI - PMC - PubMed
    1. Lun P., Ning K., Wang Y., Ma T.S.W., Flores F.P., Xiao X., Subramaniam M., Abdin E., Tian L., Tsang T.K., et al. COVID-19 Vaccination Willingness and Reasons for Vaccine Refusal. JAMA Netw. Open. 2023;6:e2337909. doi: 10.1001/jamanetworkopen.2023.37909. - DOI - PMC - PubMed

LinkOut - more resources